Published in J Natl Cancer Inst on March 29, 2013
Screening for Chemical Contributions to Breast Cancer Risk: A Case Study for Chemical Safety Evaluation. Environ Health Perspect (2015) 1.44
Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol (2014) 0.98
Development and validation of risk prediction algorithms to estimate future risk of common cancers in men and women: prospective cohort study. BMJ Open (2015) 0.91
IgE-based immunotherapy of cancer: challenges and chances. Allergy (2013) 0.89
Trends in detection of invasive cancer and ductal carcinoma in situ at biennial screening mammography in Spain: a retrospective cohort study. PLoS One (2013) 0.88
Circulating sex hormones and terminal duct lobular unit involution of the normal breast. Cancer Epidemiol Biomarkers Prev (2014) 0.88
Hormone therapy and young-onset breast cancer. Am J Epidemiol (2015) 0.87
Estrogen withdrawal, increased breast cancer risk and the KRAS-variant. Cell Cycle (2015) 0.86
Acquired convergence of hormone signaling in breast cancer: ER and PR transition from functionally distinct in normal breast to predictors of metastatic disease. Oncotarget (2014) 0.84
Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death. Br J Cancer (2014) 0.82
Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapy. Breast Cancer Res Treat (2014) 0.80
Towards research-tested smartphone applications for preventing breast cancer. Mhealth (2016) 0.80
Role of the short isoform of the progesterone receptor in breast cancer cell invasiveness at estrogen and progesterone levels in the pre- and post-menopausal ranges. Oncotarget (2015) 0.79
Botanicals and Their Bioactive Phytochemicals for Women's Health. Pharmacol Rev (2016) 0.78
Down-regulation of serum gonadotropins but not estrogen replacement improves cognition in aged-ovariectomized 3xTg AD female mice. J Neurochem (2014) 0.77
Re: Estrogen plus progestin and breast cancer incidence and mortality in the women's health initiative observational study. J Natl Cancer Inst (2013) 0.76
Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Oncotarget (2016) 0.76
Duration of Adulthood Overweight, Obesity, and Cancer Risk in the Women's Health Initiative: A Longitudinal Study from the United States. PLoS Med (2016) 0.76
Development of the Physical activity and Your Nutrition for Cancer (PYNC) smartphone app for preventing breast cancer in women. Mhealth (2017) 0.75
Distinct cognitive effects of estrogen and progesterone in menopausal women. Psychoneuroendocrinology (2015) 0.75
The molecular landscape of the normal human breast--defining normal. Breast Cancer Res (2014) 0.75
Nonsteroidal Anti-Inflammatory Drug and Aspirin Use in Relation to Lung Cancer Risk among Postmenopausal Women. Cancer Epidemiol Biomarkers Prev (2015) 0.75
Formation and Biological Targets of Quinones: Cytotoxic versus Cytoprotective Effects. Chem Res Toxicol (2016) 0.75
New Immunotherapy Strategies in Breast Cancer. Int J Environ Res Public Health (2017) 0.75
Menopausal hormone therapy and breast cancer mortality: clinical implications. Ther Adv Drug Saf (2015) 0.75
The LSP1 rs3817198 T > C polymorphism contributes to increased breast cancer risk: a meta-analysis of twelve studies. Oncotarget (2016) 0.75
The effect of estrogen plus progestin hormone therapy on breast cancer mortality: still unresolved. J Natl Cancer Inst (2013) 0.75
The Effect of Menopausal Hormone Therapies on Breast Cancer: Avoiding the Risk. Endocrinol Metab Clin North Am (2015) 0.75
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med (1995) 11.08
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Implementation of the Women's Health Initiative study design. Ann Epidemiol (2003) 7.30
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. JAMA (2003) 4.72
Concordance of self-reported data and medical record audit for six cancer screening procedures. J Natl Cancer Inst (1993) 4.29
Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst (2011) 4.14
The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause (2012) 4.04
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol (2008) 2.79
Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol (1989) 2.07
Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol (2003) 2.02
Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med (2008) 1.94
[Incidence of breast cancer before and after implementation of mammography screening]. Tidsskr Nor Laegeforen (2006) 1.71
Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res (2008) 1.53
Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol (2009) 1.52
Personalized estimates of breast cancer risk in clinical practice and public health. Stat Med (2011) 1.49
Adjusting for screening history in epidemiologic studies of cancer: why, when, and how to do it. Am J Epidemiol (2003) 1.43
Changing concepts: Menopausal hormone therapy and breast cancer. J Natl Cancer Inst (2012) 1.39
Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Res (2012) 1.37
Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause (2011) 1.31
Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther (2010) 1.30
Postmenopausal hormone use, screening, and breast cancer: characterization and control of a bias. Epidemiology (2001) 1.28
Prediagnostic use of hormone therapy and mortality after breast cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.25
Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study. Cancer Prev Res (Phila) (2011) 1.23
Recent changes in breast cancer incidence in Spain, 1980-2004. J Natl Cancer Inst (2009) 1.17
Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study. Breast Cancer Res (2008) 1.16
Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev (2008) 1.12
The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy. Maturitas (2008) 1.07
Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial. Hum Reprod (2004) 1.06
The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment. J Natl Cancer Inst (2011) 1.03
Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up. Am J Surg (2008) 1.02
Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer. Breast Cancer Res Treat (2010) 0.95
Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study. Br J Cancer (2005) 0.95
Hormone therapy and fatal breast cancer. Pharmacoepidemiol Drug Saf (2010) 0.91
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58
Long-term exposure to air pollution and incidence of cardiovascular events in women. N Engl J Med (2007) 14.90
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab (2010) 13.29
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA (2004) 11.69
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA (2003) 10.05
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials (2003) 9.97
Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. Contemp Clin Trials (2005) 9.57
A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med (2003) 9.24
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med (2004) 8.63
The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med (2002) 7.77
National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 7.68
A prospective study of self-reported sleep duration and incident diabetes in women. Diabetes Care (2003) 7.40
Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med (2002) 7.32
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Implementation of the Women's Health Initiative study design. Ann Epidemiol (2003) 7.30
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med (2012) 6.85
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Calcium/vitamin D supplementation and cardiovascular events. Circulation (2007) 6.63
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 6.62
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med (2014) 6.51
Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med (2010) 6.48
Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med (2012) 6.46
Analysis and application of European genetic substructure using 300 K SNP information. PLoS Genet (2008) 6.42
Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med (2009) 6.16
Lung cancer susceptibility locus at 5p15.33. Nat Genet (2008) 5.99
Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med (2004) 5.86
Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med (2012) 5.81
Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA (2006) 5.75
Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med (2004) 5.67